Inveltys®
Loteprednol 1% · ophthalmic suspension
Steroid
Approved uses
Inflammation and pain after ocular surgery
1 to 2 drops into the affected eye BID beginning the day after surgery, continuing through the first 2 postoperative weeks
Ocular pain clears by day 4 and anterior chamber cells by day 8.
Contraindications
- Most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella.
- Mycobacterial infection of the eye.
- Fungal diseases of ocular structures.
1% suspension (loteprednol etabonate 10 mg/mL), 2.8 mL in a 5 mL bottle
Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. Glucocorticoids bind to and activate the glucocorticoid receptor, but the molecular mechanisms are not clearly established; corticosteroids are thought to inhibit prostaglandin production. Loteprednol etabonate is lipid soluble and was structurally modified from prednisolone-related compounds to undergo a predictable transformation to an inactive metabolite. After 14 days of twice-daily unilateral dosing in healthy subjects, plasma concentrations were below the limit of quantitation (1 ng/mL). In preclinical studies, metabolites are inactive PJ-91 and PJ-90.
Warnings & Precautions
- IOP elevation and glaucoma: Prolonged corticosteroid use may produce glaucoma with optic nerve damage and defects in visual acuity and visual fields; use with caution in the presence of glaucoma and monitor IOP if the product is used 10 days or longer.
- Posterior subcapsular cataract: Corticosteroid use may produce it.
- Delayed healing after cataract surgery: Steroids may delay healing and increase the incidence of bleb formation.
- Corneal or scleral perforation: In diseases causing thinning of the cornea or sclera, perforations have occurred with topical steroids.
- Prescription renewal: The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification such as slit lamp biomicroscopy and, where appropriate, fluorescein staining.
- Secondary ocular infection: Prolonged use may suppress host response and increase the hazard of secondary ocular infection; in acute purulent conditions of the eye steroids may mask infection or enhance existing infection.
- Viral infection exacerbation: Ocular steroids may prolong the course and worsen the severity of many ocular viral infections including herpes simplex; a history of herpes simplex requires great caution.
- Fungal infections: Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application; fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use, and fungal cultures should be taken when appropriate.
- Risk of contamination: Do not allow the dropper tip to touch any surface, as this may contaminate the suspension.
- Contact lens wear: Remove lenses before instillation; the benzalkonium chloride 0.01% preservative may be absorbed by soft lenses, which may be reinserted 15 minutes after administration.
Common Side Effects
Eye pain and posterior capsular opacification, each reported in 1% of patients, were the most common adverse drug reactions in the clinical trials, and these reactions may have been the consequence of the surgical procedure. Adverse reactions associated with ophthalmic steroids include elevated IOP, which may be associated with infrequent optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, delayed wound healing and secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera. In the two registration trials, adverse events were reported more frequently on vehicle than on drug.
Pregnancy: Not absorbed systemically after topical ophthalmic administration, so maternal use is not expected to result in fetal exposure. This label carries no animal teratogenicity data.
Lactation: Not absorbed systemically by the mother after topical ophthalmic administration, so breastfeeding is not expected to expose the child.
Safety and effectiveness in pediatric patients have not been established.